查看購物車
  • English
  • Japanese
  • Korean
複雜性尿道感染市場－全球及區域分析：按國家/地區分類－分析與預測（2025-2035）
市場調查報告書
商品編碼
1906305

複雜性尿道感染市場－全球及區域分析：按國家/地區分類－分析與預測（2025-2035）

Complicated Urinary Tract Infections Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 90 Pages | 商品交期: 1-5個工作天內

價格

全球複雜性尿道感染市場－分析與預測（2025-2035）

複雜性尿道感染(cUTI) 是指泌尿道結構或功能感染疾病患者，或患有增加嚴重或性行為感染風險的潛在疾病的患者所發生的泌尿道感染。

與通常影響健康人群的非複雜性尿道感染（ cUTI）不同，複雜性泌尿道感染往往與泌尿道阻塞、留置導尿管、糖尿病、免疫抑制和神經性膀胱等因素有關。這些感染疾病可涉及下泌尿道和上泌尿道，如不及時治療，可能導致腎盂腎炎、敗血症和慢性腎臟病等嚴重併發症。

複雜性尿道感染患者通常會出現更嚴重的臨床症狀，包括高熱、腰痛和全身性發炎反應。診斷通常需要進行尿液培養，有時還需要影像檢查以確定解剖學或功能性病因。治療更為複雜，包括根據培養結果進行針對性抗生素治療，以及解決或矯正潛在的危險因子以預防復發。

由於多種因素的共同作用，包括糖尿病和免疫抑制的增加、泌尿系統異常以及尿道感染醫療設備的廣泛使用，複雜性尿道感染）的全球發病率正在穩步上升。世界衛生組織估計，全球每年約有1.5億例泌尿道感染，其中相當一部分是需要先進治療方法的複雜病例。不斷成長的患者群體直接推動了對更有效、更有針對性的治療方法的需求，從而促進了市場擴張。

此外，隨著世界人口的快速老化，易患複雜性尿道感染的患者數量顯著增加。免疫功能老齡化成長而下降，以及糖尿病和攝護腺疾病等慢性病的盛行率上升，都加劇了這種易感性。此外，老年人更可能需要留置導尿管，這進一步增加了他們的感染風險。導尿管相關尿道感染在醫療相關感染疾病中佔相當大的比例，並且仍然是醫院面臨的重大挑戰。這些人口和臨床趨勢不僅擴大了高風險患者群體，也推動了對先進抗生素、創新導尿管技術（例如抗菌塗層導尿管）以及專業感染預防策略的需求。因此，針對這一不斷成長的人群，有效應對感染疾病為複雜性尿道感染市場帶來了巨大的機會。

儘管取得了這些進展，但複雜性尿道感染市場仍面臨許多挑戰。抗生素抗藥性和治療手段的限制是限制複雜性尿道感染市場發展的主要因素。隨著細菌對標準抗生素的抗藥性日益增強，治療選擇也越來越少，使得臨床醫師難以有效控制感染疾病。這種情況好比試圖用有限的工具修補漏水，每一次失敗都會造成進一步的併發症。這些挑戰不僅影響患者的治療效果，也阻礙了製藥公司對新治療方法的投資，最終減緩了這一重要領域的市場成長和創新。

全球複雜性尿道感染(cUTI) 市場競爭異常激烈，包括 Allecra Therapeutics、Shionogi, Inc.、Melinta Therapeutics、Abbvie 和 Wockhardt Limited 在內的多家主要企業正引領創新和市場成長。這些企業處於開發創新治療方法的前沿，致力於顯著改善複雜性尿道感染(cUTI) 患者的治療效果。透過策略性研發投入，他們正在推出新型抗生素和聯合治療，旨在克服抗生素抗藥性，滿足對更有效治療方法的迫切需求。這些產業領導者透過拓展產品系列，引入新一代抗生素，並利用先進的診斷工具支持精準醫療，從而改變 cUTI 的治療格局，推動市場成長。此外，拓展新興市場並透過強大的區域分銷網路鞏固其市場地位，是更有效地覆蓋服務不足患者群體的關鍵策略。這些舉措正在鞏固他們的市場地位，並加速他們在競爭激烈且快速發展的 cUTI 治療領域的成長。

複雜性尿道感染（cUTI）市場區隔：

細分 1：按區域

  • 北美洲
  • 歐洲
  • 亞太地區

複雜性尿道感染（cUTI）市場的擴張，進一步得益於人們對院內感染（HAI）預防的日益重視，這為cUTI市場帶來了新的機會。全球各地的醫院都面臨越來越大的壓力，需要降低導尿管相關尿道感染（CAUTI）的發生率，CAUTI佔所有醫療相關感染的40%之多。監管政策和處罰措施正促使醫院採用先進的預防解決方案，例如抗菌塗層導尿管、快速診斷工具和感染控制技術。這為開發創新抗生素、導尿管技術和感染監測系統的公司創造了巨大的市場機遇，因為醫院渴望投資於能夠降低感染率、改善患者預後並降低整體治療成本的解決方案。

目錄

執行摘要

1. 全球複雜性尿道感染市場：產業分析

  • 市場概覽與生態系統
  • 流行病學分析
  • 主要市場趨勢
    • 影響分析
  • 監管狀態
  • 管道分析
  • 市場動態
    • 概述
    • 市場促進因素
    • 市場限制
    • 市場機遇

2. 全球複雜性尿道感染市場（按地區分類），價值，2024-2035年

  • 北美洲
    • 市場動態
    • 市場規模及預測
    • 2024-2035年北美複雜性尿道感染市場（百萬美元）按國家分類
  • 歐洲
    • 市場動態
    • 市場規模及預測
    • 2024-2035年歐洲複雜性尿道感染市場（百萬美元）按國家分類
  • 亞太地區
    • 市場動態
    • 市場規模及預測
    • 亞太地區複雜性尿道感染市場（按國家分類，百萬美元），2024-2035年

第3章：競爭格局與公司概況

  • 競爭格局
    • 併購
    • 夥伴關係、聯盟和業務拓展
    • 新服務
    • 監理活動
    • 資金籌措活動
  • 公司簡介
    • Akero Therapeutics.
    • Sagimet Biosciences.
    • Boehringer Ingelheim.
    • 89bio.
    • Inventiva Pharma.
    • Galmed Pharmaceuticals.
    • Novo Nordisk A/S.
    • Viking Therapeutics.
    • Hepion Pharmaceuticals.
    • Pfizer, Inc.
    • HighTide Biopharma.
    • Boston Pharmaceuticals.
    • Rivus Pharmaceuticals.
    • Lipocine.
    • Aligos Therapeutics.
    • MediciNova.
    • Eli Lilly and Company.
    • 其他

第4章調查方法

Product Code: BHL3534SA

Global Complicated Urinary Tract Infections Market, Analysis and Forecast: 2025-2035

Complicated urinary tract infections (cUTIs) are infections of the urinary system that occur in individuals with structural or functional urinary tract abnormalities or in those with underlying conditions that increase the risk of severe or recurrent infection. Unlike uncomplicated UTIs, which typically affect otherwise healthy individuals, cUTIs are often associated with factors such as urinary obstruction, indwelling catheters, diabetes mellitus, immunosuppression, or neurogenic bladder. These infections can involve both the lower and upper urinary tract, potentially leading to serious complications such as pyelonephritis, sepsis, or chronic kidney disease if not promptly treated.

Patients with cUTIs often present with more severe clinical symptoms, including high fever, flank pain, and systemic inflammatory responses. Diagnosis usually requires urine culture and, in many cases, imaging studies to identify anatomical or functional causes. Treatment is more complex and involves targeted antibiotic therapy based on culture results, alongside addressing or correcting the underlying predisposing factors to prevent recurrence.

The global prevalence of complicated urinary tract infections is steadily rising, driven by a combination of factors including increasing rates of diabetes, immunosuppression, urinary tract abnormalities, and widespread use of indwelling medical devices. According to global health estimates, urinary tract infections account for approximately 150 million cases annually worldwide, and a significant proportion of these are complicated cases requiring advanced treatment approaches. The growing patient burden directly drives the demand for more effective and targeted therapeutics, contributing to market expansion.

Additionally, the global elderly population is expanding rapidly, leading to a significant rise in individuals who are more vulnerable to complicated urinary tract infections. Age-related declines in immune function, along with higher rates of chronic conditions such as diabetes and prostate disorders, contribute to this increased susceptibility. In addition, older adults are more likely to require urinary catheters, which further elevates their risk of infection. Catheter-associated urinary tract infections remain a major challenge in hospitals, representing a substantial portion of healthcare-associated infections. This demographic and clinical trend not only broadens the at-risk patient pool but also drives demand for advanced antibiotics, innovative catheter technologies like antimicrobial-coated devices, and specialized infection prevention strategies. As a result, effectively addressing infections in this growing segment presents a significant opportunity for the complicated urinary tract infections market.

Despite these advances, the complicated urinary tract infections market faces several challenges. Antibiotic resistance and treatment limitations are major factors restraining the complicated urinary tract infections market. As bacteria increasingly resist standard antibiotics, treatment options become fewer and less effective, making it harder for clinicians to manage infections successfully. This scenario is similar to trying to fix a leak with limited tools, each failed attempt complicates the situation further. These challenges not only impact patient outcomes but also discourage pharmaceutical companies from investing in new therapies, ultimately slowing market growth and innovation in this critical area.

The global complicated urinary tract infections market is highly competitive, with several leading companies driving innovation and market growth, such as Allecra Therapeutics, Shionogi, Inc., Melinta Therapeutics, Abbvie, and Wockhardt Limited. These companies are at the forefront of developing innovative therapies that are significantly improving patient outcomes in the complicated urinary tract infections (cUTIs) market. Through strategic investments in research and development (R&D), they are introducing novel antibiotics and combination therapies specifically designed to overcome antibiotic resistance and address the urgent need for more effective treatments. By expanding their product portfolios with next-generation antimicrobials and leveraging advanced diagnostic tools to support precision treatment, these industry leaders are reshaping the landscape of cUTI care and driving market growth. Additionally, expanding into emerging markets and strengthening their presence through robust regional distribution networks are key strategies to reach underserved patient populations more effectively. These approaches are enabling companies to solidify their market position and accelerate growth in the competitive and rapidly evolving cUTI treatment arena.

Complicated Urinary Tract Infections Market Segmentation:

Segmentation 1: by Region

  • North America
  • Europe
  • Asia-Pacific

The expansion of the complicated urinary tract infections market is further driven by increasing focus on hospital-acquired infection (HAI) prevention as an opportunity for the cUTI market. Hospitals worldwide are under growing pressure to reduce catheter-associated urinary tract infections (CAUTIs), which account for up to 40% of all healthcare-associated infections. Regulatory policies and financial penalties incentivize hospitals to adopt advanced prevention solutions, such as antimicrobial-coated catheters, rapid diagnostic tools, and infection control technologies. This creates a significant market opportunity for companies developing innovative antibiotics, catheter technologies, and infection monitoring systems, as hospitals are willing to invest in solutions that lower infection rates, improve patient outcomes, and reduce overall treatment costs.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Complicated Urinary Tract Infections Market: Industry Analysis

  • 1.1 Market Overview and Ecosystem
  • 1.2 Epidemiological Analysis
  • 1.3 Key Market Trends
    • 1.3.1 Impact Analysis
  • 1.4 Regulatory Landscape
  • 1.5 Pipeline Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Overview
    • 1.6.2 Market Drivers
    • 1.6.3 Market Restraints
    • 1.6.4 Market Opportunities

2. Global Complicated Urinary Tract Infections Market (by Region), Value ($Million), 2024-2035

  • 2.1 North America
    • 2.1.1 Market Dynamics
    • 2.1.2 Market Sizing and Forecast
    • 2.1.3 North America Complicated Urinary Tract Infections Market, by Country ($Million), 2024-2035
      • 2.1.3.1 U.S.
  • 2.2 Europe
    • 2.2.1 Market Dynamics
    • 2.2.2 Market Sizing and Forecast
    • 2.2.3 Europe Complicated Urinary Tract Infections Market, by Country ($Million), 2024-2035
      • 2.2.3.1 U.K.
      • 2.2.3.2 France
      • 2.2.3.3 Germany
      • 2.2.3.4 Italy
      • 2.2.3.5 Spain
  • 2.3 Asia-Pacific
    • 2.3.1 Market Dynamics
    • 2.3.2 Market Sizing and Forecast
    • 2.3.3 Asia-Pacific Complicated Urinary Tract Infections Market, by Country ($Million), 2024-2035
      • 2.3.3.1 Japan

3. Competitive Landscape and Company Profiles

  • 3.1 Competitive Landscape
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Partnership, Alliances and Business Expansion
    • 3.1.3 New Offerings
    • 3.1.4 Regulatory Activities
    • 3.1.5 Funding Activities
  • 3.2 Company Profiles
    • 3.2.1 Akero Therapeutics.
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Sagimet Biosciences.
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 Boehringer Ingelheim.
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 89bio.
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Inventiva Pharma.
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 Galmed Pharmaceuticals.
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
      • 3.2.6.6 Analyst View
    • 3.2.7 Novo Nordisk A/S.
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Top Competitors
      • 3.2.7.4 Target Customers/End-Users
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 Viking Therapeutics.
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products / Product Portfolio
      • 3.2.8.3 Top Competitors
      • 3.2.8.4 Target Customers/End-Users
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View
    • 3.2.9 Hepion Pharmaceuticals.
      • 3.2.9.1 Overview
      • 3.2.9.2 Top Products / Product Portfolio
      • 3.2.9.3 Top Competitors
      • 3.2.9.4 Target Customers/End-Users
      • 3.2.9.5 Key Personnel
      • 3.2.9.6 Analyst View
    • 3.2.10 Pfizer, Inc.
      • 3.2.10.1 Overview
      • 3.2.10.2 Top Products / Product Portfolio
      • 3.2.10.3 Top Competitors
      • 3.2.10.4 Target Customers/End-Users
      • 3.2.10.5 Key Personnel
      • 3.2.10.6 Analyst View
    • 3.2.11 HighTide Biopharma.
      • 3.2.11.1 Overview
      • 3.2.11.2 Top Products / Product Portfolio
      • 3.2.11.3 Top Competitors
      • 3.2.11.4 Target Customers/End-Users
      • 3.2.11.5 Key Personnel
      • 3.2.11.6 Analyst View
    • 3.2.12 Boston Pharmaceuticals.
      • 3.2.12.1 Overview
      • 3.2.12.2 Top Products / Product Portfolio
      • 3.2.12.3 Top Competitors
      • 3.2.12.4 Target Customers/End-Users
      • 3.2.12.5 Key Personnel
      • 3.2.12.6 Analyst View
    • 3.2.13 Rivus Pharmaceuticals.
      • 3.2.13.1 Overview
      • 3.2.13.2 Top Products / Product Portfolio
      • 3.2.13.3 Top Competitors
      • 3.2.13.4 Target Customers/End-Users
      • 3.2.13.5 Key Personnel
      • 3.2.13.6 Analyst View
    • 3.2.14 Lipocine.
      • 3.2.14.1 Overview
      • 3.2.14.2 Top Products / Product Portfolio
      • 3.2.14.3 Top Competitors
      • 3.2.14.4 Target Customers/End-Users
      • 3.2.14.5 Key Personnel
      • 3.2.14.6 Analyst View
    • 3.2.15 Aligos Therapeutics.
      • 3.2.15.1 Overview
      • 3.2.15.2 Top Products / Product Portfolio
      • 3.2.15.3 Top Competitors
      • 3.2.15.4 Target Customers/End-Users
      • 3.2.15.5 Key Personnel
      • 3.2.15.6 Analyst View
    • 3.2.16 MediciNova.
      • 3.2.16.1 Overview
      • 3.2.16.2 Top Products / Product Portfolio
      • 3.2.16.3 Top Competitors
      • 3.2.16.4 Target Customers/End-Users
      • 3.2.16.5 Key Personnel
      • 3.2.16.6 Analyst View
    • 3.2.17 Eli Lilly and Company.
      • 3.2.17.1 Overview
      • 3.2.17.2 Top Products / Product Portfolio
      • 3.2.17.3 Top Competitors
      • 3.2.17.4 Target Customers/End-Users
      • 3.2.17.5 Key Personnel
      • 3.2.17.6 Analyst View
    • 3.2.18 Others

4. Research Methodology

List of Figures

  • Figure: Complicated Urinary Tract Infections Market (by Scenario), $Million, 2024, 2030, and 2035
  • Figure: Global Complicated Urinary Tract Infections Market, 2024 and 2035
  • Figure: Global Complicated Urinary Tract Infections Market Key Trends, Impact Analysis
  • Figure: North America Complicated Urinary Tract Infections Market, $Million, 2024-2035
  • Figure: Europe Complicated Urinary Tract Infections Market, $Million, 2024-2035
  • Figure: Asia-Pacific Complicated Urinary Tract Infections Market, $Million, 2024-2035

List of Tables

  • Table: Market Snapshot
  • Table: Market Dynamics
  • Table: Global Complicated Urinary Tract Infections Market (by Region), $Million, 2024-2035